For example, treatment with CDK4/6 inhibitors induces the upregulation of MYC protein levels, the subsequent increase in glutamine catabolism and activation of the mTOR pathway.147 As a result, CDK4/6 and GLS1 inhibitors demonstrate a synergistic effect in inhibiting proliferation and viability of cancer cells. This evidence concerns the gene GLS and cancer.